Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, China.
Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou 311121, China.
Cells. 2022 May 16;11(10):1652. doi: 10.3390/cells11101652.
The Chimeric antigen receptor (CAR)-T cell therapy has made inroads in treating hematological malignancies. Nonetheless, there are still multiple hurdles in CAR-T cell therapy for solid tumors. Primary CAR-expressing macrophage cells (CAR-Ms) and induced pluripotent stem cells (iPSCs)-derived CAR-expressing macrophage cells (CAR-iMacs) have emerged as attractive alternatives in our quest for an efficient and inexpensive approach for tumor immune cell therapy. In this review, we list the current state of development of human CAR-macrophages and provide an overview of the crucial functions of human CAR-macrophages in the field of tumor immune cell therapy.
嵌合抗原受体 (CAR)-T 细胞疗法在治疗血液系统恶性肿瘤方面取得了进展。然而，在实体瘤的 CAR-T 细胞治疗中仍然存在多个障碍。原代表达嵌合抗原受体的巨噬细胞 (CAR-M) 和诱导多能干细胞 (iPSC) 衍生的表达嵌合抗原受体的巨噬细胞 (CAR-iMac) 作为一种高效且廉价的肿瘤免疫细胞治疗方法的替代品，已经引起了广泛的关注。在这篇综述中，我们列出了人源 CAR-巨噬细胞的当前发展状态，并概述了人源 CAR-巨噬细胞在肿瘤免疫细胞治疗领域的关键作用。
